Empirical Therapy with Piperacillin/Tazobactam in Patients with Suspected Infection at Ratchaburi Hospital
Keywords:
piperacillin/tazobactam, empiric treatment, multidrug-resistant infectionsAbstract
Objectives: The aim is to determine the incidence of multidrug-resistant infections in patients who received empiric antibiotic with piperacillin/tazobactam, including characteristics of these infected patients and mortality rate, in Ratchaburi Hospital.
Method: This is a retrospective descriptive study by collecting data from medical records and laboratory results of 727 in-patients who received empiric antibiotic with piperacillin/tazobactam between 1 April 2022 to 30 June 2022. Characteristic data were collected, including gender, age, co-morbidities, ward, duration of piperacillin/tazobactam therapy, history of hospitalization within one year, and suspected hospital acquired infection.
Results: The incidence rate of multidrug-resistant infections was 12.1% and pathogen which susceptible to piperacillin/tazobactam was 54.5%. The statistically significant factors in multidrug resistant infected patients were the duration from the 1st day of admission to empiric treatment (p = .026). There was no difference in patients suspected hospital acquired infection (p = .556) and a history of hospitalization within one year (p = .556). The mortality rate among patients with suspected infection who received piperacillin/tazobactam was 37.4%.
Conclusion: Piperacillin/tazobactam should be considered in cases of suspected infection in the patients with the duration from the 1st day of admission to empiric treatment beyond 4.74 days. Carefully monitor medicine ward or patients who are infected with piperacillin/tazobactam susceptible bacteria due to significant increasing rate of mortality.
References
ภาณุมาศ ภูมาศ, ตวงรัตน์ โพธะ, วิษณุ ธรรมลิขิตกุล, และคณะ. ผลกระทบด้านสุขภาพ และเศรษฐศาสตร์ จากการติดเชื้อดื้อยาต้านจุลชีพในประเทศไทย: การศึกษาเบื้องต้น. วารสารวิจัยระบบสาธารณสุข 2555;6(3):352–360.
Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 2021;47(11):1181–1247. doi: 10.1007/s00134-021-06506-y.
Ishida T, Ito A, Washio Y, et al. Risk factors for drug-resistant pathogens in immunocompetent patients with pneumonia: Evaluation of PES pathogens. J Infect Chemother 2017;23(1):23–8. doi: 10.1016/j.jiac.2016.09.002.
Namikawa H, Yamada K, Fujimoto H, et al. Clinical characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing escherichia coli at a tertiary hospital. Intern Med 2017;56(14):1807–15. doi: 10.2169/internalmedicine.56.7702.
Menéndez R, Méndez R, Polverino E, et al. Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. BMC Infect Dis 2017;17(1):659. doi: 10.1186/s12879-017-2754-5.
Bhattarai S, Sharma BK, Subedi N, et al. Burden of Serious Bacterial Infections and multidrug-resistant organisms in an adult population of nepal: a comparative analysis of minimally invasive tissue sampling informed mortality surveillance of community and hospital deaths. Clin Infect Dis 2021;73(Suppl_5):S415–S421. doi: 10.1093/cid/ciab773.
Kumar M, Jain S, Shree N, et al. Incidence rate of multidrug-resistant organisms in a tertiary care hospital, North Delhi. Apollo Medicine 2015;12(4):248–256. doi: 10.1016/j.apme.2015.07.006.
Alsehemi AF, Alharbi EA, Alammash BB, et al. Assessment of risk factors associated with multidrug-resistant organism infections among patients admitted in a tertiary hospital - a retrospective study. Saudi Pharm J. 2023;31(6):1084-1093. doi:10.1016/j.jsps.2023.03.019
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
